The global Haemophilus influenzae type B vaccine market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing number of cases of HIB infections and the introduction of new vaccines in the market.
The global Haemophilus influenzae type B vaccine market can be segmented on the basis of type, application, and region. On the basis of type, it can be divided into liquid monovalent HIB, liquid combination HIB, lyophilized monovalent HIB and lyophilized combination HIB. On the basis of application it can be divided into hospital use, research institutions use, pharmaceutical and biotechnology companies use and academic institutions use. On the basis on region it can be divided into North America (US & Canada), Latin America (Mexico & Brazil), Europe (Germany & France), Asia Pacific (China) and Middle East & Africa (Saudi Arabia).
Some Of The Growth Factors Of This Market:
- Increasing prevalence of HIB in children below the age of 5 years is one of the major factors driving the growth of this market.
- Increasing awareness about HIB and its complications among parents and healthcare professionals is also driving the growth of this market.
- The increasing number of vaccines being developed for HIB are also contributing to the growth in this market.
- Increasing government funding for research on HIB vaccine development is also contributing to the growth in this market.
Industry Growth Insights published a new data on “Haemophilus Influenzae Type B Vaccine Market”. The research report is titled “Haemophilus Influenzae Type B Vaccine Market research by Types (Liquid Monovalent HIB, Liquid Combination HIB, Lyophilized Monovalent HIB, Lyophilized Combination HIB), By Applications (Hospital, Research Institutions, Pharmaceutical and Biotechnology Companies, Academic Institutions, Other), By Players/Companies Novartis, Merck, Sanofi, GlaxoSmithKline, Takeda Pharmaceuticals Company, Walvax Biotechnology, Lanzhou Institute of Biologica, Immunize BC”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Haemophilus Influenzae Type B Vaccine Market Research Report
By Type
Liquid Monovalent HIB, Liquid Combination HIB, Lyophilized Monovalent HIB, Lyophilized Combination HIB
By Application
Hospital, Research Institutions, Pharmaceutical and Biotechnology Companies, Academic Institutions, Other
By Companies
Novartis, Merck, Sanofi, GlaxoSmithKline, Takeda Pharmaceuticals Company, Walvax Biotechnology, Lanzhou Institute of Biologica, Immunize BC
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Haemophilus Influenzae Type B Vaccine Market Report Segments:
The global Haemophilus Influenzae Type B Vaccine market is segmented on the basis of:
Types
Liquid Monovalent HIB, Liquid Combination HIB, Lyophilized Monovalent HIB, Lyophilized Combination HIB
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research Institutions, Pharmaceutical and Biotechnology Companies, Academic Institutions, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Merck
- Sanofi
- GlaxoSmithKline
- Takeda Pharmaceuticals Company
- Walvax Biotechnology
- Lanzhou Institute of Biologica
- Immunize BC
Highlights of The Haemophilus Influenzae Type B Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liquid Monovalent HIB
- Liquid Combination HIB
- Lyophilized Monovalent HIB
- Lyophilized Combination HIB
- By Application:
- Hospital
- Research Institutions
- Pharmaceutical and Biotechnology Companies
- Academic Institutions
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Haemophilus Influenzae Type B Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Haemophilus influenzae type B vaccine is a vaccine that helps protect against Haemophilus influenzae infections. It is made from a weakened form of the bacterium, and it can help prevent serious illnesses, such as meningitis, pneumonia, and ear infections. The vaccine is given by injection into the arm or leg.
Some of the key players operating in the haemophilus influenzae type b vaccine market are Novartis, Merck, Sanofi, GlaxoSmithKline, Takeda Pharmaceuticals Company, Walvax Biotechnology, Lanzhou Institute of Biologica, Immunize BC.
The haemophilus influenzae type b vaccine market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Haemophilus Influenzae Type B Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Haemophilus Influenzae Type B Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Haemophilus Influenzae Type B Vaccine Market - Supply Chain
4.5. Global Haemophilus Influenzae Type B Vaccine Market Forecast
4.5.1. Haemophilus Influenzae Type B Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Haemophilus Influenzae Type B Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Haemophilus Influenzae Type B Vaccine Market Absolute $ Opportunity
5. Global Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Type
5.3.1. Liquid Monovalent HIB
5.3.2. Liquid Combination HIB
5.3.3. Lyophilized Monovalent HIB
5.3.4. Lyophilized Combination HIB
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Research Institutions
6.3.3. Pharmaceutical and Biotechnology Companies
6.3.4. Academic Institutions
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Haemophilus Influenzae Type B Vaccine Demand Share Forecast, 2019-2026
9. North America Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Research Institutions
9.4.3. Pharmaceutical and Biotechnology Companies
9.4.4. Academic Institutions
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Type
9.7.1. Liquid Monovalent HIB
9.7.2. Liquid Combination HIB
9.7.3. Lyophilized Monovalent HIB
9.7.4. Lyophilized Combination HIB
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Haemophilus Influenzae Type B Vaccine Demand Share Forecast, 2019-2026
10. Latin America Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Research Institutions
10.4.3. Pharmaceutical and Biotechnology Companies
10.4.4. Academic Institutions
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Type
10.7.1. Liquid Monovalent HIB
10.7.2. Liquid Combination HIB
10.7.3. Lyophilized Monovalent HIB
10.7.4. Lyophilized Combination HIB
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Haemophilus Influenzae Type B Vaccine Demand Share Forecast, 2019-2026
11. Europe Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Research Institutions
11.4.3. Pharmaceutical and Biotechnology Companies
11.4.4. Academic Institutions
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Haemophilus Influenzae Typ B Vaccine Market Size and Volume Forecast by Type
11.7.1. Liquid Monovalent HIB
11.7.2. Liquid Combination HIB
11.7.3. Lyophilized Monovalent HIB
11.7.4. Lyophilized Combination HIB
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Haemophilus Influenzae Type B Vaccine Demand Share, 2019-2026
12. Asia Pacific Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Research Institutions
12.4.3. Pharmaceutical and Biotechnology Companies
12.4.4. Academic Institutions
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Type
12.7.1. Liquid Monovalent HIB
12.7.2. Liquid Combination HIB
12.7.3. Lyophilized Monovalent HIB
12.7.4. Lyophilized Combination HIB
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Haemophilus Influenzae Type B Vaccine Demand Share, 2019-2026
13. Middle East & Africa Haemophilus Influenzae Type B Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Research Institutions
13.4.3. Pharmaceutical and Biotechnology Companies
13.4.4. Academic Institutions
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Haemophilus Influenzae Type B Vaccine Market Size and Volume Forecast by Type
13.7.1. Liquid Monovalent HIB
13.7.2. Liquid Combination HIB
13.7.3. Lyophilized Monovalent HIB
13.7.4. Lyophilized Combination HIB
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Haemophilus Influenzae Type B Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Haemophilus Influenzae Type B Vaccine Market: Market Share Analysis
14.2. Haemophilus Influenzae Type B Vaccine Distributors and Customers
14.3. Haemophilus Influenzae Type B Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GlaxoSmithKline
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Takeda Pharmaceuticals Company
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Walvax Biotechnology
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Lanzhou Institute of Biologica
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Immunize BC
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
